Glooko announced this month that it’s teaming up to connect Novo Nordisk‘s (NYSE:NVO) insulin pens with the company’s diasend diabetes management solution.
Novo Nordisk plans to launch its connected insulin pens, the NovoPen 6 and NovoPen Echo Plus, in early 2019. Any provider using diasend and any person using the diasend mobile app will be able to sync data from Novo Nordisk’s connected pens, according to Glooko.
The company also noted that it plans to offer compatibility with Dexcom‘s (NSDQ:DXCM) G6 continuous glucose monitor.
“Until now, data from insulin pens was [sic] self-reported and subject to error, or often simply not captured. Our partnership with Novo Nordisk enables this insulin data to be seamlessly synced to diasend, where patients and providers can easily see the data correlated with glucose levels, activity information and more. This allows much more informed conversations and decisions about the insulin regimen as well as other aspects of the treatment plan” Glooko CEO Russ Johannesson said in prepared remarks.
“Our partnership with Glooko is already helping healthcare professionals to better understand their patients’ diabetes management,” Søren Smed Østergaard, VP of digital health at Novo Nordisk, added. “By integrating our connected, durable insulin pens with the diasend mobile app, we will soon help people manage their disease and access healthcare when they need it.”
In July last year, Insulet (NSDQ:PODD) announced that it inked a deal with Glooko to connect data from Insulet’s Omnipod insulin delivery products in Europe with Glooko’s diabetes software.
